ANVS
Annovis Bio IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$94.87M
P/E Ratio
—
EPS
$-1.71
Beta
1.26
52W High
$5.50
52W Low
$1.54
50-Day MA
$2.13
200-Day MA
$2.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Annovis Bio Inc
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -301.10% |
| Return on Assets | -120.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.11 |
| Price-to-Book | 30.35 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $42.54M |
| Float | $24.58M |
| % Insiders | 13.88% |
| % Institutions | 16.77% |
Historical Volatility
HV 10-Day
70.23%
HV 20-Day
82.07%
HV 30-Day
72.27%
HV 60-Day
106.75%
HV Rank
22.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($12.50 target)
1
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026